1991 – to date             BioPlanta GmbH 
President and CEO
● Development and Manufacturing of stem cell products
● Clinical Trial and Licensing of stem cell pharmaceuticals and tissue   engineered products 
2017 – 2018             Bergmann AG 
Chief Business Development Officer; since 12/2017 Chief    Financial Officer 
● General Management, budgeting and controlling 
● Development of international cooperation 
● Merger & Acquisition
2012 – 2017             Vita 34 AG (Frankfurt Stock Exchange, prime standard)    
Chief Executive Officer 
● General Management, responsible for strategy, production, new    products, Research & Development, Investor Relation,    shareholder    attendance 
● International     Business Development 
● Development of new     products for stem cell banking    (due to    GMP    and pharmaceutical guidelines) 
● Application for pharmaceutical approvals, international    accreditation